J&J Expands Access To HIV Drug Prezista In Africa, But Won’t Join Patent Pool
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson will not enforce patents on its HIV drug Prezista (darunavir) for sub-Saharan Africa and other least developed countries provided generic firms make high-quality versions, the company said.